A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. The gene discussed is HSPH1; the disease is B-cell non-Hodgkin lymphoma.